Compare ABR & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ABR | ACHV |
|---|---|---|
| Founded | 2003 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 809.7M | 726.5M |
| IPO Year | 2003 | 2018 |
| Metric | ABR | ACHV |
|---|---|---|
| Price | $4.05 | $7.55 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | $9.90 | ★ $14.67 |
| AVG Volume (30 Days) | ★ 4.1M | 1.4M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 15.42% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.06 | $2.62 |
| 52 Week High | $12.58 | $8.64 |
| Indicator | ABR | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 23.12 | 47.78 |
| Support Level | N/A | $7.01 |
| Resistance Level | $5.41 | $8.63 |
| Average True Range (ATR) | 0.16 | 0.39 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 2.06 | 37.94 |
Arbor Realty Trust Inc is a specialized real estate finance company. It invests in a diversified portfolio of structured finance assets in the multifamily, SFR, and commercial real estate markets, consisting of bridge and mezzanine loans, including junior participating interests in first mortgages, preferred, and direct equity. In addition, it may also directly acquire real property and invest in real estate-related notes and certain mortgage-related securities. The company has two business segments, Structured Business and Agency Business. It generates a majority of its revenue from the Structured Business Segment.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.